Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F20%3A10409684" target="_blank" >RIV/00216208:11140/20:10409684 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/20:10409684

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=7t~B388hTf" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=7t~B388hTf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.14063" target="_blank" >10.21873/anticanres.14063</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Popis výsledku v původním jazyce

Immunotherapy based on immune checkpoint inhibitors (ICIs) represents a novel anticancer treatment strategy. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed cell death-1 receptor (PD1) and programmed cell death-1 ligand (PD-L1) have shown efficacy and safety in the treatment of various malignancies. Some of them have recently found their place in a routine clinical practice, while others are at different phases of clinical trials. Treatment with ICIs may be accompanied by undesirable impairment of immunotolerance to non-tumoural tissues, leading to a specific side-effect also called immune-related adverse events (irAE). There is an increasing body of evidence that the development of irAEs is associated with a beneficial effect of immunotherapy, thus it has become a hot topic in the field of clinical oncology. This review is focused on data from recently published studies evaluating the association between irAEs and outcome of patients with cancer treated with ICIs.

Název v anglickém jazyce

Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Popis výsledku anglicky

Immunotherapy based on immune checkpoint inhibitors (ICIs) represents a novel anticancer treatment strategy. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed cell death-1 receptor (PD1) and programmed cell death-1 ligand (PD-L1) have shown efficacy and safety in the treatment of various malignancies. Some of them have recently found their place in a routine clinical practice, while others are at different phases of clinical trials. Treatment with ICIs may be accompanied by undesirable impairment of immunotolerance to non-tumoural tissues, leading to a specific side-effect also called immune-related adverse events (irAE). There is an increasing body of evidence that the development of irAEs is associated with a beneficial effect of immunotherapy, thus it has become a hot topic in the field of clinical oncology. This review is focused on data from recently published studies evaluating the association between irAEs and outcome of patients with cancer treated with ICIs.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

40

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

9

Strana od-do

1219-1227

Kód UT WoS článku

000522732700003

EID výsledku v databázi Scopus

2-s2.0-85081390210